Organization | General Electric

General Electric Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Schenectady NY United States (1892)

Status: Acquired by Danaher (2019)

Organization Overview

First Clinical Trial

2003

NCT00209391

First Marketed Drug

1951

iopanoic acid (telepaque)

First NDA Approval

1951

iopanoic acid (telepaque)

Last Known Activity

2021

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (41)

Key: General Electric (40) Acquired (1)

albumin (Human) (Plasbumin) (1997)

calcium (1974)

calcium-47 (1968 NDA)

cyanocobalamin (berocca) (1974)

cyanocobalamin co-57 (rubratope-57) (1974)

cyanocobalamin co-58 (1974 NDA)

diatrazoate meglumine (Renografin) (1954 NDA)

etidronic acid (1976)

fibrinogen, i-125 (ibrin)

fluoroestradiol (Cerianna) (2020)

flutemetamol F-18 (vizamyl) (2013 NDA)

gadodiamide (Omniscan) (1993 NDA)

gadoteric acid (Dotarem) (2019)

gallium citrate ga 67 (1977)

indium in-111 (1992 NDA)

iobenguane (123i) (2008 NDA)

iodixanol (visipaque) (1996 NDA)

iodohippurate sodium i-123 (Nephroflow) (1984 NDA)

ioflupane i-123 (2011 NDA)

iohexol (Omnipaque) (1985 NDA)

iopanoic acid (telepaque) (1951 NDA)

meglumine (1974 NDA)

metrizamide (amipaque) (1978 NDA)

metrizoic acid (1973 NDA)

mpi indium dtpa in 111 (1982 NDA)

radiolabeled albumin technetium Tc-99m albumin colloid kit (Microlite) (1976 NDA)

Radiopharmaceutical (1980 NDA)

selenomethionine se-75 (1976)

sodium fluoride (18F) (1972 NDA)

sodium iodide i-123 (1976 NDA)

succimer (Chemet) (1982)

technetium-99m exametazine (Ceretec) (1988 NDA)

technetium tc-99m medronate kit (1979)

technetium tc-99m pentetate kit (renotec) (1974)

technetium tc-99m polyphosphate kit (sodium polyphosphate-tin kit) (1982 NDA)

technetium tc-99m sulfur colloid kit (Tesuloid) (1976)

technetium tc-99m tetrofosmin kit (Myoview) (1996 NDA)

thallous chloride ti 201 (1982)

tyropanoate sodium (bilopaque) (1969 NDA)

ultra-technekow fm (1974)

xenon xe-133 (1976)

Drugs in Phase 4 Trials (23)

Key: General Electric (22) Acquired (1)

acetylcysteine (mucomyst) (1 trial)

diatrazoate meglumine (Renografin) (2 trials)

evolocumab (repatha) (1 trial)

fluoroestradiol (Cerianna) (1 trial)

gadobenate (Multihance) (1 trial)

gadobutrol (gadavist) (1 trial)

gadodiamide (Omniscan) (4 trials)

gadoteric acid (Dotarem) (1 trial)

gadoteridol (prohance) (1 trial)

gadoxetate disodium (eovist) (1 trial)

glucose monohydrate (1 trial)

hexyl 5-aminolevulinate (Cysview) (1 trial)

iobenguane (123i) (10 trials)

iodixanol (visipaque) (13 trials)

iohexol (Omnipaque) (3 trials)

iopamidol (Isovue) (4 trials)

iopromide (ultravist) (2 trials)

ioversol (optiray) (2 trials)

nicorandil (1 trial)

perflutren protein-type a microspheres (Optison) (5 trials)

sodium bicarbonate (2 trials)

technetium tc-99m tetrofosmin kit (Myoview) (1 trial)

thallous chloride ti 201 (1 trial)

Drugs in Phase 3 Trials (13)

Key: General Electric (12) Acquired (1)

adenosine (Adenocard) (1 trial)

barium sulphate (Varibar) (1 trial)

dipyridamole (persantine) (1 trial)

florbetapir (Amyvid) (2 trials)

flurpiridaz (2 trials)

flutemetamol F-18 (vizamyl) (9 trials)

ioflupane i-123 (5 trials)

omega-3 fatty acids (Omacor) (1 trial)

perfluorobutane (Sonazoid) (5 trials)

potassium iodide (thyro-block) (1 trial)

potassium perchlorate (perchloracap) (1 trial)

regadenoson (lexiscan) (3 trials)

sulfur hexafluoride lipid-type a microspheres (Lumason) (1 trial)

Drugs in Phase 2 Trials (19)

Key: General Electric (17) Acquired (2)

123i-altropane (1 trial)

18f-rgd (1 trial)

68ga-rm2 (2 trials)

bay86-7548 (1 trial)

cisplatin (platinol) (1 trial)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

epirubicin (ellence) (1 trial)

Fluciclovine (Axumin) (6 trials)

Ga 68 PSMA-11 (Illuccix) (2 trials)

insulin human (humulin) (1 trial)

ioforminol (3 trials)

ixabepilone (ixempra) (1 trial)

liraglutide (victoza) (1 trial)

paclitaxel (taxol) (1 trial)

platelet-rich plasma (1 trial)

sitagliptin (januvia) (1 trial)

strontium-89 (1 trial)

tc99m maraciclatide (1 trial)

Drugs in Phase 1 Trials (13)

13c-pyruvate (2 trials)

18f-ftc-146 (2 trials)

fludeoxyglucose f-18 (2 trials)

fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (1 trial)

insulin lispro (humalog) (1 trial)

motexafin gadolinium (1 trial)

pyruvate (1 trial)

technetium tc-99m sestamibi (Cardiolite) (1 trial)

yellow fever vaccine 17d strain (1 trial)

Drugs in Other Trials (8)

cabergoline (dostinex) (1 trial)

carbidopa (sinemet) (1 trial)

dexmedetomidine (precedex) (1 trial)

fluorothymidine (1 trial)

levodopa (larodopa) (1 trial)

midazolam (versed) (1 trial)

remifentanil (ultiva) (1 trial)

simethicone (IMODIUM) (1 trial)

Indications

Approved Indications

Alzheimer Disease

Cardiovascular Diseases

Parkinsonian Disorders

Pheochromocytoma

Spinal Diseases

Ventricular Dysfunction, Left

Experimental Indications (Clinical Trials, Phases 1-4)

Alzheimer Disease (Phase 3)

Amyloidosis (Phase 3)

Arterial Occlusive Diseases (Phase 3)

Atrophy (Phase 3)

Body Weight (Phase 4)

Breast Neoplasms (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Cardiomyopathies (Phase 4)

Carotid Artery Diseases (Phase 2)

Chronic Pain (Phase 1)

Cognitive Dysfunction (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Dementia (Phase 3)

Dementia, Vascular (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Embolism (Phase 4)

Fatty Liver (Phase 2)

Fever (Phase 1)

Glioma (Phase 1)

Head and Neck Neoplasms (Phase 2)

Heart Diseases (Phase 2)

Heart Failure (Phase 3)

Hydrocephalus (Phase 3)

Hydrocephalus, Normal Pressure (Phase 3)

Hypertension, Pulmonary (Phase 4)

Hypothyroidism (Phase 4)

Infarction (Phase 4)

Ischemia (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Promyelocytic, Acute (Phase 1)

Lewy Body Disease (Phase 3)

Liver Diseases (Phase 2)

Lung Neoplasms (Phase 4)

Melanoma (Phase 2)

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Multiple System Atrophy (Phase 3)

Myocardial Ischemia (Phase 4)

Neuralgia (Phase 1)

Neuroblastoma (Phase 3)

Nociceptive Pain (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Parkinson Disease (Phase 3)

Pheochromocytoma (Phase 3)

Prostatic Neoplasms (Phase 2)

Pulmonary Embolism (Phase 4)

Recurrence (Phase 4)

Renal Artery Obstruction (Phase 4)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Sarcoma (Phase 2)

Sclerosis (Phase 1)

Shy-Drager Syndrome (Phase 3)

Supranuclear Palsy, Progressive (Phase 3)

Syndrome (Phase 3)

Triple Negative Breast Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 4)

Uterine Neoplasms (Phase 2)

Ventricular Dysfunction (Phase 4)

Ventricular Dysfunction, Left (Phase 4)

Yellow Fever (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 101
# of Trial APIs: 76